¿ AnalytiCon AG, of Berlin, and Bayer AG, of Leverkusen, Germany, entered a two-year under which AnalytiCon will use its separation and elucidation technologies to isolate, purify and characterize thousands of novel natural products from biomaterials proprietary to Bayer. AnalytiCon is expected to receive DM6 million (US$3.2 million) in the collaboration.
¿ Tm Bioscience, of Toronto, entered into an agreement with Drug Discovery Limited, of Glasgow, Scotland, to explore the use of specific DNA-binding compounds developed by DDL in Tm's proprietary DNA hybridization control assays. Tm said any successful compounds will be available for exclusive use for incorporation into its enabling technologies that will be developed through licensing or other strategies.
¿ StressGen Biotechnologies Inc., of Victoria, British Columbia, implemented a collaborative research program with the National Jewish Medical and Research Center in Denver, Colo., a world leader in lung and allergic diseases. The program was implemented following the results from preclinical studies of a stress protein-based allergy and asthma therapy. StressGen's stress protein or stress proteins fused to appropriate antigens were shown to reduce levels of the cytokines which fuel allergic reactions. In addition, these experiments indicated the technology lowers IgE levels and non-specific pulmonary hyperreactivity.